Palliative effects of morinda citrifolia oil and juice

Abstract

A method of preventing and treating various ailments and diseases by utilizing the Cox-2 selective inhibition characteristics of processed Morinda citrifolia.

1 . A method for selectively inhibiting Cox-2 relative to Cox-1 in mammals, the method comprising: 
 administering to a mammal a composition comprising a processed  Morinda citrifolia  juice, wherein said  Morinda citrifolia  juice is present in an amount between about 2.0% and 10% by volume.    
   
   
       2 . The method of  claim 1 , wherein the  Morinda citrifolia  is processed.  
   
   
       3 . The method of  claim 1 , wherein the  Morinda citrifolia  is in liquid form.  
   
   
       4 . The method of  claim 1 , wherein the  Morinda citrifolia  is included as an ingredient in a food product.  
   
   
       5 . The method of  claim 1 , wherein the  Morinda citrifolia  is in capsule form.  
   
   
       6 . The method of  claim 1 , wherein said dose of  Morinda citrifolia  inhibits the production of Cox-2-related prostaglandins that cause inflammation-induced disease, while at the same time inhibiting to a lesser extent, the production of Cox-1 related prostaglandins.  
   
   
       7 - 8 . (canceled)  
   
   
       9 . A method of treating and preventing disease comprising the steps of: obtaining a quantity of  Morinda citrifolia  juice and pulp; filtering the wet pulp from the juice; 
 pasteurizing the juice; and    providing a dose of said  Morinda citrifolia  juice for consumption; and inhibiting Cox-2 to a greater extent than Cox-1.    
   
   
       10 . The method of  claim 9 , wherein the  Morinda citrifolia  juice is included as an ingredient in a food product.  
   
   
       11 . A method of  claim 9 , wherein said dose is administered in an amount that is pre-determined to limit undesired Cox-1 inhibition relative to Cox-2 inhibition.  
   
   
       12 . A method of treating and preventing disease comprising the steps of: obtaining a quantity of  Morinda citrifolia  juice and pulp; filtering the wet pulp from the juice, wherein the wet pulp has a fiber content of from 10% to 40%, by weight;  
     pasteurizing the pulp;  
     providing a therapeutic dose of said  Morinda citrifolia  pulp for consumption; and, inhibiting Cox-2 to a greater extent than Cox-1.  
   
   
       13 . The method of  claim 12 , wherein the  Morinda citrifolia  pulp is included as an ingredient in a food product.  
   
   
       14 . The method of  claim 12 , wherein said dose is administered in an amount that is predetermined to limit undesired Cox-1 inhibition relative to Cox-2 inhibition.  
   
   
       15 . A method of alleviating the symptoms, preventing and further inhibiting the proliferation of certain diseases and maladies in mammals, said method comprising the steps of: administering to a patient, at least two ounces of processed  Morinda citrifolia  juice twice daily on an empty stomach for a period of at least two months, wherein said step of administering to a patient will have the physiological effect of inhibiting Cox-2 to a greater extent than Cox-1.  
   
   
       16 . The method of  claim 15 , wherein said diseases comprise those selected from the group consisting of cancer of the colon; cancer of the esophagus; skin cancer; lung cancer; cancer of the bladder; cancer of the stomach; breast cancer; head and neck cancer; prostate cancer; cancer of the pancreas; well-differentiated hepatocellular carcinomas; Alzheimer's disease; neuro-degenerative diseases; inflammation-induced diseases; heart disease; osteoporosis and diabetes.  
   
   
       17 . The method as recited  claim 1 , wherein the said composition further comprises  Morinda citrifolia  oil.  
   
   
       18 . The method as recited in  claim 1 , wherein the said composition further comprises pulp blended in with juice to form a puree.  
   
   
       19 . The method as recited in  claim 1 , further comprising a step of providing a composition comprising  Morinda citrifolia  juice present in an amount between 2.0% and 10% by volume to treat an inflammation-endues disease with a human.  
   
   
       20 . A method for selectively inhibiting COX-2 relative to COX-1 comprising: 
 administering to a mammal a composition comprising a processed  Morinda citrifolia  juice two times per day, wherein said dosage is less than 0.1 ml per kg of body weight of the mammal